Alumis Inc. Common Stock
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALMS research report →
Companywww.alumis.com
Alumis Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases.
- CEO
- Martin Babler
- IPO
- 2021
- Employees
- 168
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $2.71B
- P/E
- -11.59
- P/S
- 322.43
- P/B
- 4.85
- EV/EBITDA
- -6.27
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 89.63%
- Op Margin
- -5364.02%
- Net Margin
- -2825.70%
- ROE
- -54.63%
- ROIC
- -71.89%
Growth & Income
- Revenue
- $24.05M · 0.00%
- Net Income
- $-243,325,000 · 17.30%
- EPS
- $-2.86 · 72.45%
- Op Income
- $-427,204,000
- FCF YoY
- -44.14%
Performance & Tape
- 52W High
- $30.60
- 52W Low
- $2.76
- 50D MA
- $24.21
- 200D MA
- $14.83
- Beta
- -0.29
- Avg Volume
- 1.34M
Get TickerSpark's AI analysis on ALMS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 1, 26 | Foresite Labs, LLC | other | 1,123,337 |
| Apr 1, 26 | Foresite Labs, LLC | other | 680,486 |
| Apr 1, 26 | Foresite Labs, LLC | other | 1,123,337 |
| Apr 1, 26 | Foresite Capital Management VI LLC | other | 1,123,337 |
| Apr 1, 26 | Foresite Capital Management VI LLC | other | 680,486 |
| Apr 1, 26 | Foresite Capital Management VI LLC | other | 1,123,337 |
| Apr 1, 26 | Tananbaum James B. | other | 1,123,337 |
| Apr 1, 26 | Tananbaum James B. | other | 680,486 |
| Apr 1, 26 | Tananbaum James B. | other | 1,123,337 |
| Dec 31, 25 | Goldstein David M | other | 0 |
Our ALMS Coverage
We haven't published any research on ALMS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ALMS Report →